Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Windtree TherapeuticsWINT +100.00% 6-1 Month Momentum % is -17.78% as of Jul. 31, 2026. The stock has 2 warning signs investors should review. Among 1,383 Biotechnology companies, Windtree Therapeutics ranks worse than 53.15% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-07-31), Windtree Therapeutics's 6-1 Month Momentum % is -17.78%.
The industry rank for Windtree Therapeutics's 6-1 Month Momentum % or its related term are showing as below:
WINT's 6-1 Month Momentum % is ranked worse than 53.15% of 1383
companies
in the Biotechnology industry
Industry Median: -14.26
vs WINT: -17.78
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Windtree Therapeutics 6-1 Month Momentum % Related Terms
WINT vs VRTX, REGN, RVMD: 6-1 Month Momentum % Comparison
For the Biotechnology subindustry, Windtree Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windtree Therapeutics 6-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Windtree Therapeutics's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windtree Therapeutics (WINT) has a 6-1 Month Momentum % of -17.78% as of Jul. 31, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Windtree Therapeutics and its competitors. According to the industry distribution chart, Windtree Therapeutics ranks #735 out of 1383 companies in the Biotechnology industry, placing it in the top 53.1%.
Is Windtree Therapeutics' 6-1 Month Momentum % too high?
Windtree Therapeutics' current 6-1 Month Momentum % is -17.78%. Based on the distribution chart, Windtree Therapeutics ranks #735 out of 1383 companies in the Biotechnology industry, which is below the industry midpoint.
How does Windtree Therapeutics' 6-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Windtree Therapeutics ranks #735 out of 1383 companies for 6-1 Month Momentum %. This places Windtree Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Windtree Therapeutics and its competitors. Windtree Therapeutics's current 6-1 Month Momentum % is -17.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windtree Therapeutics stock overvalued right now?
Windtree Therapeutics (WINT) has a current 6-1 Month Momentum % of -17.78%. The current 6-1 Month Momentum % is -17.78%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Windtree Therapeutics (WINT), the current 6-1 Month Momentum % is -17.78% as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WINT has been successfully added to your 
